Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2015

Filed with the SEC on May 7, 2015 and accepted by EDGAR at May 7, 2015, 16:30 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-01-01 to 2015-03-31$0us-gaap:SalesRevenueGoodsNet
Research and development3 months2015-01-01 to 2015-03-31$0us-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-01-01 to 2015-03-31−$124.8kus-gaap:OperatingIncomeLoss
Interest expense3 months2015-01-01 to 2015-03-31$169.5kus-gaap:InterestExpense
Net income3 months2015-01-01 to 2015-03-31−$294.4kus-gaap:NetIncomeLoss
Basic EPS3 months2015-01-01 to 2015-03-31$0.00us-gaap:EarningsPerShareBasic
Operating cash flow3 months2015-01-01 to 2015-03-31−$113.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2015-03-31$148.7kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-03-31$148.7kus-gaap:AssetsCurrent
Total assetsAt period end2015-03-31$148.7kus-gaap:Assets
Total liabilitiesAt period end2015-03-31$379.2kus-gaap:Liabilities
Shareholders' equityAt period end2015-03-31−$230.5kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-15-002193. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.